A company that manufactures generic drugs announced Tuesday that it would build a research and development hub in Durham, creating 275 jobs.

Aurobindo Pharma USA Inc. plans to invest $31.7 million in the operation, which will serve as the company’s national headquarters for specialty pharmaceutical R&D.

“We are very excited about our plans for expansion of our specialty pharma R&D and manufacturing in North Carolina,” Ninad Deshpanday, Aurobindo’s president for R&D, said in a statement. “North Carolina has one of the best talent pools in the specialty pharma R&D and manufacturing sectors, and we look forward to establishing a large and successful footprint here.”

New Jersey-based Aurobindo is a unit of Aurobindo Pharma Ltd. of India, a leading maker of semi-synthetic penicillin which also makes neuroscience, cardiovascular, anti-retroviral, anti-diabetic and gastroenterology drugs.

The company already employs 14 people in Raleigh.

The new jobs will have a total annual payroll of $17.1 million, officials said.

State officials approved a Job Development Investment Grant of up to $3.8 million for Aurobindo. The company must meet job and investment targets each year over 12 years to receive the maximum amount of the JDIG, which refunds some of the state employee withholding tax to the firm.


Web Editor: Matthew Burns